Immunicum AB represents a strong set of values and corporate philosophy. The company focuses on advancing innovative immunotherapies to enhance cancer treatment outcomes. Immunicum AB is dedicated to improving patients' lives by creating therapies that harness the power of the immune system. Their commitment to scientific excellence, integrity, and patient-centeredness sets them apart. Additionally, a collaborative approach, in-depth research, and strategic partnerships drive their success. Immunicum AB's corporate philosophy revolves around staying at the forefront of immunotherapy advancements to deliver effective and targeted solutions for cancer patients.

Immunicum AB is primarily present in Sweden.

Immunicum AB, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully completed its Phase I/II clinical trial evaluating the safety and efficacy of its innovative cancer immunotherapy, ilixadencel. Immunicum AB has also initiated a Phase II trial investigating the use of ilixadencel in combination with checkpoint inhibitors for the treatment of kidney cancer. Furthermore, the company received Fast Track designation from the U.S. FDA for ilixadencel in metastatic renal cell carcinoma. These milestones highlight Immunicum AB's dedication to advancing novel immunotherapies and its potential to revolutionize cancer treatment.

Immunicum AB is a Swedish biopharmaceutical company founded in 2002. The company focuses on developing immunotherapies to treat various types of cancer. Immunicum's core technology is based on a unique allogeneic cell-based therapeutic approach called "ilixadencel." This technology harnesses the patient's immune system to fight cancer and enhance the effectiveness of other cancer treatments. Immunicum's research and development efforts have resulted in several clinical trials to evaluate the safety and efficacy of ilixadencel in various indications, including kidney cancer, liver cancer, and gastrointestinal stromal tumors. With a strong commitment to advancing cancer treatment, Immunicum AB is dedicated to providing innovative solutions for patients battling cancer.

The main competitors of Immunicum AB in the market are a few prominent companies. Some of the noteworthy competitors include AstraZeneca, Bristol-Myers Squibb, and Merck & Co. These companies also specialize in the field of immunotherapy and are engaged in developing innovative treatments for various diseases and conditions. Immunicum AB, with its unique and potential immunotherapy candidates, competes with these companies in terms of research, development, and commercialization of therapeutic solutions.

Immunicum AB is primarily active in the biotechnology industry.

The business model of Immunicum AB revolves around developing and commercializing innovative immunotherapies for the treatment of various solid tumors. Immunicum focuses on utilizing the unique properties of its proprietary technology platform, called the INTUVAX system, to stimulate the patient's own immune system against cancer cells. This personalized approach aims to activate and strengthen the immune response, enhancing the effectiveness of cancer treatment. By harnessing the potential of immunotherapy, Immunicum aims to provide patients with improved outcomes and better quality of life. Immunicum AB is committed to advancing its pipeline of novel immunotherapies to address unmet medical needs in oncology.

Mendus AB (publ) KGV ir -1,35.

Mendus AB (publ) KUV ir 114,47.

AlleAktien kvalitātes vērtējums Mendus AB (publ) ir 4/10.

gaidāmā Mendus AB (publ) apgrozījums ir 1,56 milj. SEK.

gaidāmā Mendus AB (publ) peļņa ir -132,27 milj. SEK.

Immunicum AB is a Swedish biotechnology company specializing in the development of therapies to combat cancer. Founded in 2002, the company has established itself as one of the leading companies in the field of immunotherapy. The company is divided into two divisions: Immunicum Clinical and Immunicum Research. In the Immunicum Clinical division, the company focuses on the development of immunoncological therapies that stimulate the body's immune system to recognize and destroy cancer cells. This includes the development of cellular immunotherapy products made from donor cells. These cells are injected into the patient's body to help the immune system fight cancer. On the other hand, Immunicum Research is focused on researching new treatment options to combat cancer. This includes identifying new cellular targets and developing new immunotherapy products. Immunicum AB's leading product is Immunicum-PRV-031, a personalized immunotherapy treatment made from the patient's dendritic cells. These cells are manipulated to recognize specific tumor antigens and trigger a T-cell response in the patient's body. This immune reaction is intended to fight and destroy cancer. In addition, Immunicum AB is also developing other immunotherapy products such as Immunicum-IL2-001. This product contains Interleukin-2 (IL-2), a well-known protein that stimulates the body's immune system to recognize and fight tumor antigens. Currently, this product is still in the clinical testing phase. The company has established various partnerships with other companies and research institutions to support its research and development efforts. This includes partnerships with Pfizer and the Karolinska Institute. Immunicum AB's business model is based on the research and development of immunoncological therapies to combat cancer. The company holds a leading position in this field and uses it to develop personalized immunotherapies and other treatment options. Immunicum AB collaborates closely with other companies and research institutions to advance its research and development. The company has the potential to become a key player in the field of cancer therapy and improve the lives of patients worldwide.

Mendus AB (publ) izmaksā dividendes 0 SEK, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Mendus AB (publ) vai uzņēmums nedod dividendes.

Mendus AB (publ) ISIN ir SE0005003654.

Mendus AB (publ) WKN ir A1W59F.

Mendus AB (publ) simbols ir IMMU.ST.

Pēdējo 12 mēnešu laikā Mendus AB (publ) maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Mendus AB (publ) plāno maksāt dividendes 0 SEK apmērā.

Mendus AB (publ) pašreizējā dividendu rentabilitāte ir .

Mendus AB (publ) maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Mendus AB (publ) pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 SEK. Tas atbilst dividendes ražībai 0 %.

Mendus AB (publ) tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Mendus AB (publ) apmērā 0 SEK, kas tika izmaksāta 12.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 12.09.2024..

Pēdējās dividendes izmaksa notika 12.09.2024..

Gadā 2023, Mendus AB (publ) izmaksāja 0 SEK dividendes.

Mendus AB (publ) dividendes tiek izmaksātas SEK.